The relation between treatment and prognosis of childhood membranoproliferative glomerulonephritis

Figures & data

Table 1. The features of the patients at presentation.

	n	%
Hematuria	33	100
Macroscopic hematuria	13	39.4
Nephrotic syndrome	23	69.7
Non-nephrotic proteinuria	10	30.3
Hypertension	18	54.5
Renal failure	9	27.2
Hypocomplemantemia	19	57.5
Low C3	14
Low C3 and C4	5

Table 2. The demographic features, presentation findings, treatment regimens and prognosis of the patients.

Sex	Age (years)	Follow-up period (months)	eGFR onset	eGFR latest	NS	HT	HC	Presentation features	Treatment*,**	Prognosis
F	13	132	47	114	+	−	+	NS + RF	PMP, P	CR
M	13	47	73	104	+	−	−	NS + RF	PMP, P	CR
M	10	68	105	141	+	+	+	NS	PMP, P	PR
F	13.5	68	80	116	+	+	+	NS + RF	PMP, P	PR
M	8	120	138	140	−	−	−	NNP	P	CR
M	12.5	96	102	109	+	−	−	NS	PMP, P	CR
M	9	50	121	149	−	−	+	NNP	P	CR
M	14	63	108	120	+	+	−	NS	PMP, P	CR
M	12	74	74	113	+	−	−	NS + RF	PMP, P	CR
M	7.5	87	35	115	+	−	−	NS + RF	PMP, P	CR
M	12	78	86	106	+	+	+	NS + RF	PMP, P	CR
M	14	44	116	142	+	+	+	NS	PMP, P	CR
M	6	81	111	129	+	+	+	NS	PMP, P	PR
F	8	63	108	118	+	−	+	NS	PMP, P	PR
M	12	84	116	127	+	−	−	NS	PMP, P	CR
F	7.5	80	95	95	+	+	−	NS	PMP, P	PR
M	7.5	96	99	122	−	−	+	NNP	–	CR
M	8	60	126	162	−	−	+	NNP	P	CR
M	10	87	97	24	−	+	+	NNP	P, PMP, Cyp	CRD
F	7	144	127	47	−	−	+	NNP	P, PMP, Cyp	CRD
M	13	95	124	140	+	+	+	NS	PMP, P, Cs	NS
F	4	96	69	18	−	+	+	NNP + RF	PMP, P, Cyp	CRD
F	10.5	26	102	116	+	+	+	NS	PMP, P	CR
M	5	60	99	94	+	+	+	NS	PMP, P	CR
F	14	58	135	45	+	+	+	NS	PMP, P, MMF	CRD
F	10	72	92	59	−	−	−	NNP	P, PMP, Cyp	CRD
F	10	128	128	158	+	−	−	NS	PMP, P	CR
M	15	74	129	106	+	+	−	NS	PMP, P	PR
F	7	42	54	120	+	+	−	NS + RF	PMP, P	CR
F	13	66	132	105	−	+	−	NNP	P	PR
M	15	72	146	137	−	+	+	NNP	P	CR
M	14	34	76	150	+	−	−	NS + ;RF	PMP, P	CR
F	13	28	119	147	+	+	+	NS	PMP, P	CR

Notes: *All patients were given dipyridamole and angiotensin converting enzyme inhibitor.

**The treatments written as bold show the treatment used.

F, female; M, male; RF, renal failure; NS, nephrotic syndrome; HT, hypertension; HC, hypocomplementemi; CRD, chronic renal disease; CR, complete remission; PR, partial remission; PMP, pulse methylprednisolone; P, prednisolone; Cyp, cyclophosphamide; MMF, mycophenolate mofetil; Cs, cyclosporine.

Table 3. The prognosis of the patients.

Presentation features	Complete remission (%)	Partial remission (%)	Nephrotic syndrome (%)	CRD (%)
Nephrotic syndrome n = 15	8	5	1	1
Nephrotic syndrome  + renal failure n = 8	7	1	-	-
Non-nephrotic proteinuria n = 9	5	1	-	3
Non-nephrotic proteinuria  + renal failure n = 1	–	–	-	1
n = 33	20 (60.6%)	7 (21.2%)	1 (3%)	5 (15.2%)